Pharmaceutical

Macau approves IASO Bio’s multiple myeloma therapy

The Macau Special Administrative Region (ISAF) Pharmaceutical Administration Bureau has approved IASO Bio's NDA for equecabtagene autoleucel.

Mar 29, 2025 - 06:00
Macau approves IASO Bio’s multiple myeloma therapy
The Macau Special Administrative Region (ISAF) Pharmaceutical Administration Bureau has approved IASO Bio's NDA for equecabtagene autoleucel.
Read the original article

Tags:

Previous Article

Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug

Next Article

MSD’s subcutaneous Keytruda non-inferior to IV version of blockbuster drug

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Listen: When do tests hurt more than help?

Opinion: Listen: When do tests hurt more than help?

Dec 13, 2023

The next privacy battle will be fought over health data

The next privacy battle will be fought over health data

Aug 4, 2023

Early signals suggest oral SERD’s potential for more breast cancer patients

Early signals suggest oral SERD’s potential for more br...

May 30, 2023